Informa Life Sciences is part of the Knowledge and Networking Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.
Head of Immuno-Oncology at Gilead Sciences
Dr Wilson is currently Executive Director of Immuno-modulatory Drug Discovery at Agenus Inc., an immuno-oncology company focused on the discovery and development of new treatments for human cancers. He received his Ph.D. from the Walter and Elisa Hall Institute, University of Melbourne (Australia) studying the mechanism of dendritic cell antigen processing and presentation via MHC class I and class II. He completed his postdoctoral training at Genentech Inc, where he explored the cross-talk between Fc gamma receptor (FcgammaR) biology and TNFR superfamily agonist antibodies, including the seminal finding of an FcgammaR-mediated anti-TNFR antibody clustering mechanism. He has since held positions at Novartis and more recently at Merck KGaA (EMD Serono), where he was he was Head of Immunobiology.